PrisMax for Continuous Renal Replacement Therapy FDA Cleared

Baxter won FDA clearance for its PrisMax system and accompanying TherMax blood warmer. The system is designed for delivery of continuous renal replacement therapy to treat those with acute kidney injury and some autoimmune diseases.

The system is an evolution of the company’s Prismaflex technology that has been available for a few years, and is now optimized to seamlessly work with in-hospital EMRs, and features smart pump settings that guarantee that proper amounts of fluid are removed and that the therapy prescriptions are met.

The system helps to reduce the amount of oversight and management from clinicians while improving performance. Additionally, there’s the ability to select auto-effluent drain or effluent bag drain configurations.

“We looked at every detail during the PrisMax design process. Our team reviewed every piece of feedback from nephrologists, nurses and intensive care specialists, and then designed a system that can help simplify therapy administration and maximize efficiency,” said Gavin Campbell, general manager of Baxter’s U.S. renal business, in a press release. “We put our 20 years of expertise in continuous renal replacement therapy and blood filtering technology to design an advanced system that allows for clinicians to customize treatment parameters to meet the needs of their patients.”

Flashback: Baxter’s PrixMax Renal Replacement and Organ Support System Cleared in Europe

Product page: PRISMAX

Via: Baxter

Medgadget Editors

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.